Echo Therapeutics, Inc., a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced that, after numerous consultations with the Chinese government, its strategic partner, Medical Technologies Innovation Asia, Ltd., believes that Echo’s locally produced needle-free CGM products will be designated as a Class 2 medical device.

View original post here:
Echo’s non-invasive CGM system to be designated as Class 2 medical device in China

Scroll to Top